How many institutional investors hold GLUE?

2 tracked institutional investors disclosed a position in GLUE (MONTE ROSA THERAPEUTICS INC) in their most recent 13F filing.

Who is the largest institutional holder of GLUE?

Stanley Druckenmiller, Duquesne Family Office, holds the largest disclosed position in GLUE, valued at $7M.

Where does this GLUE ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

GLUE — MONTE ROSA THERAPEUTICS INC

Name: MONTE ROSA THERAPEUTICS INC (GLUE) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying GLUE?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence

Institutional Conviction

Net accumulation · 1 buying vs 0 selling last quarter

Macro Tailwind

Macro conditions are mixed for this sector

Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their GLUE position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence

+1 tracked investor added or increased positions last quarter (Stanley Druckenmiller)
+2 tracked investors reported holding GLUE at their latest filing
+Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource

Contradicting evidence — always shown

−13F data is disclosed up to 45 days after quarter end — positions may have changed since

Know the limits

· 13F disclosure lag (up to 45 days)
· Tracked investors are a sample, not the whole market
· Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About MONTE ROSA THERAPEUTICS INC (GLUE)

MONTE ROSA THERAPEUTICS INC (GLUE) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Stanley Druckenmiller (Duquesne Family Office), valued at $7M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in GLUE

/100

Institutional Accumulation

Added / Increased2

Reduced0

Exited1

BearishBullish

Crowded Trade Score™

How many top investors track GLUE

/100

Undiscovered

2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded

151015+

GLUE Ownership Composition

How MONTE ROSA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Macro

63% of tracked value

Institutions

tracked investors

Total Reported

$11.4M

combined 13F value

Macro63.3%
Multi-Strategy / Quant36.7%

Macro(1)

63.3%

Multi-Strategy / Quant(1)

36.7%

Tracked investors currently reporting GLUE

2 tracked investors have since exited this position — listed separately below.

Investor	Firm	Shares	Market value	% of portfolio	As of
Stanley Druckenmiller	Duquesne Family Office	297.6K	$7.2M	0.14%	Jun 30, 2026
Ken Griffin	Citadel Advisors	172.4K	$4.2M	0.00%	Jun 30, 2026

Stanley DruckenmillerJun 30, 2026
Duquesne Family Office
Shares
297.6K
Value
$7.2M
% Portfolio
0.14%
Ken GriffinJun 30, 2026
Citadel Advisors
Shares
172.4K
Value
$4.2M
% Portfolio
0.00%

Previously held GLUE

These investors reported GLUE in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

Investor	Firm	Last reported shares	Value then	Last held
Izzy Englander	Millennium Management	191.4K	$3.1M	Mar 31, 2026
Steve Cohen	Point72 Asset Management	90.4K	$670K	Sep 30, 2025

Recent activity

Investor	Action	Δ %	Current value	Filing date
Steve Cohen	New	—	$1.7K	Feb 14, 2025
Steve Cohen	Sold	-100.00%	$0	Jul 21, 2025
Stanley Druckenmiller	New	—	$7.2M	Aug 14, 2026

Steve Cohen
New
$1.7KFeb 14, 2025
Steve Cohen
Sold
$0(-100.00%)Jul 21, 2025
Stanley Druckenmiller
New
$7.2MAug 14, 2026

Frequently asked questions

How many institutional investors hold GLUE?: 2 tracked institutional investors disclosed a position in GLUE (MONTE ROSA THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of GLUE?: Stanley Druckenmiller, Duquesne Family Office, holds the largest disclosed position in GLUE, valued at $7M.
Did institutional ownership of GLUE increase or decrease?: Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 fully exited GLUE.
Where does this GLUE ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.